ClinicalTrials.gg

Program

farabursen

In Novartis's pipeline, MIR17 inhibitor. Its studies are mostly in Polycystic Kidney, Autosomal Dominant, led by Novartis.

Furthest: phase 1, since May 26, 20222 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis20 open or runningphase 1since May 26, 2022May 26, 2022none ahead
  • Named in Novartis’s own pipeline as CYX082 (farabursen), phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 26, 2022First study: phase 1 study in Polycystic Kidney, Autosomal DominantFirst studyNCT05429073 · 32 enrolled · United States
  2. Aug 24, 2022Phase 1 study in Polycystic Kidney, Autosomal DominantNCT05521191 · 68 enrolled · United States

TargetBeta

“MIR17 inhibitor”the company's pipeline, read by Claude · source

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT05521191Polycystic Kidney, Autosomal Dominant · United States1CompletedJan 27, 202568
NCT05429073Polycystic Kidney, Autosomal Dominant · United States1CompletedSep 8, 202232

How it is read

Names in the registry

  • “RGLS8429”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.